U.S. Markets closed

Deciphera Pharma's late-stage stomach cancer study meets main goal

Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

The study tested the treatment, ripretinib, in 129 patients with advanced gastrointestinal stromal tumors. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)